

PRESS RELEASE

Applied Spectral Imaging (ASI), a ZYTOMICS Company, announces the release of its new software version 8.4.2, featuring integrated digital workflows for pathology and cytogenetics laboratories

CARLSBAD, CA, July 22, 2026 - Applied Spectral Imaging (ASI), a global provider of biomedical imaging solutions, has launched GenASIs version 8.4.2, introducing new capabilities designed to streamline pathology and cytogenetics workflows.

As diagnostic laboratories continue to face increasing workload, growing demand for digital implementation, and the need for scalable and secure IT infrastructures, GenASIs v8.4.2 strengthens ASI's software performance, scalability, cybersecurity alignment and interoperability, while expanding its footprint in digital pathology and maintaining its leadership in cytogenetics.

With GenASIs version 8.4.2, ASI introduces a brand-new product to its pathology portfolio, HiPath FL, designed to support fluorescence whole slide imaging (WSI)*. The new version also features PortalLink to export FISH images and results to external image management portals, expanded ScanLink Pathology functionality to import brightfield images in DICOM format, a new computer-aided metaphase detection system for karyotyping applications, as well as significant IT updates and full compliance with latest regulatory and data security requirements.

"GenASIs version 8.4.2 represents an important step forward in ASI's commitment to offer integrated, efficient, and future-ready laboratory workflows" says Avishai Landau, VP Imaging & Digital Solutions at ZYTOMICS and General Manager at ASI. "By enabling synchronous review of H&E, IHC, IF and/or FISH WSI side-by-side, ASI helps laboratories more precisely target regions of interest for high-magnification tissue FISH scanning, and digitally correlate protein expression with morphological context in skin or renal immunofluorescent (IF) specimens."

With the release of its latest software version, ASI empowers laboratories to accelerate their transition to digital workflows. By integrating digital pathology and cytogenetics into a single All-in-One platform, laboratories can streamline operations, reduce costs, minimize instrument footprint, and simplify staff training. Designed to address laboratories' growing technological and regulatory expectations, ASI's new release v8.4.2 further unifies pathology and cytogenetics workflows while improving efficiency and operational flexibility.

About Applied Spectral Imaging (ASI), a ZYTOMICS Company

Applied Spectral Imaging (ASI), a ZYTOMICS Company, is a global leader in biomedical imaging with a comprehensive product portfolio for karyotyping, FISH, digital pathology, IHC, immunofluorescence and spectral imaging. Combining ASI's imaging expertise with ZYTOMICS' extensive portfolio of ISH probes, reagents and automation, laboratories benefit from flexible solutions that enhance efficiency, accuracy, and diagnostic confidence.

ASI's product portfolio is FDA-cleared for BandView Karyotyping, FISHView, SpotScan for CEP XY, UroVysion, ALK and HER2/neu FISH, and HiPath IHC Family for HER2, ER, PR and Ki67 in manual configuration. The ASI product family is IVDR compliant.

Founded in 1993, ASI develops, markets, services and supports its products in more than 80 countries.



For more information about ASI, please visit www.spectral-imaging.com
or e-mail sales@spectral-imaging.com



(*) Features for research use only (RUO)